@nmasc_@steph_palazzolo For those without Information subs (sorry), can you let us know if the article mentions why the shares were authorised at such a steep discount?
@chamath Hi Chamath,
Your aforemwntioned trends appear to be manifesting themselves in London as well.
But a side thought - with GPs beginning to prioritise DPI, do you think third party secondary firms are now in a better position to negotiate lower entry prices?
@NoahP_2@Pharmdca I understand, and agree with, the qualitative analysis, but why do you put the 1bln price tag on it? Also, with a float of c. 26mln shares, a 1bln buyout gives a price of c. 38 - correct me if I’m incorrect.